Introduction
Haemodialysis is too expensive in both manpower and finlance to provide treatment for all patients with irreversible renal failure.' Successful kidney transplantation therefore offers the only hope of solving the cruel dilemma of kidney failure, in which treatment for all patients is possible in theory, but not in practice. Unfortunately the success of cadaveric kidney transplants has not improved greatly over the last decade, despite widespread use of HLA matching. Most series report one-year success rates of about 5000. In Scandinavia 90 transplants with four HLA antigen matches had a one-year survival rate of 5400, and in North America 83 similar "full-house" four-antigen matches produced a one-year survival rate of 46°0.2 Conversely, HLA unmatched ABO compatible kidneys have given a one-year survival rate of 4000. These results leave little doubt that HLA compatibility plays only a minor part in transplant survival, at least by HLA matching as currently performed. On the other hand, genetic matching is of major importance because kidney transplantation between identical twins is almost invariably successful. It may be concluded, therefore, that tissue matching is important, but present methods of HLA typing do not identify the major histocompatibility antigens relevant to kidney transplantation.
By a comparison with live donor-related transplants the degree of success that is theoretically possible in cadaver kidney transplants may be estimated. Live donor transplants between parents and children have a success rate of about 800o, regardless of HLA matching, which suggests that comparable success might be possible in cadaver transplants under ideal conditions. The degree of success in related transplants mainly depends on a high degree of genetic compatibility between parent and child. Although they share an HLA haplotype, they may still have two HLA antigen mismatches. Cadaver transplants with two HLA mismatches have a much lower success rate (about 40%0), which suggests that the degree of genetic identity between parent and child may be due to a genetic system that is probably distinct from the-HLA system, at least as identified at present. If the genetic markers or antigens responsible for the success of parent-child transplants could be Royal Southern Hospital, Liverpool L8 5SH RONALD FINN, MD, FRCP, consultant physician C A ST HILL, MB, FRCPATH, consultant pathologist identified, then comparable success might be expected in cadaver transplants.
We have pointed out3-5 that _lucidating the im-munological mechanism that protects the fetal allograft should provide information leading to a new approach to organ transplantation, and we have recently reported such a mechanism. 6 We now suggest an alternative approach to organ transplantation based on the successful survival of the fetal allograft.
Survival of the fetal allograft
Medawar7 first pointed out that the fetus was genetically foreign to its mother and logically should be rejected, and this concept of the fetus as an allograft was developed by Anderson.8 Earlier theories to explain the survival of the fetal allograft, such as immaturity of the fetal antigens and the placental barrier, have not been substantiated, and the immunological mechanism responsible for protecting the fetal allograft has only recently been identified.6 Using the bidirectional mixed lymphocyte culture technique maternal and fetal cells fail to react with each other. As the lymphocyte is the most active immunological cell it is unlikely thlat cells of lesser immunological potential will react, and hence the mother and fetus are tolerant of each other. The mechanism responsible for this to!erance is multifactorial. Maternal and fetal cells share genetic markers that lessen reactions between them, and any residual incompatibility reaction is readily suppressed by the immunosuppressive agents present in pregnancy. These agents include a-fetoprotein, chorionic gonadotrophin, and other pregnancy-specific glycoproteins. Fetal T lymphocytes also may produce a suppressor substance that can pass through a cell filter and inhibit the growth of maternal lymphocytes.9 10 We emphasise the critical point that the tolerance between maternal and fetal cells can be shown only with the use of the two-way mixed lymphocyte reaction (MLR). The one-way MLR does not show the same degree of suppression because the tolerance is at least partly due to an active mechanism requiring the viability of both cell populations.
The liberation of suppressor substances by the fetal T lymphocytes is an active process, and the genetic recognition of similarity between maternal and fetal cells may also depend on cell viability.
Proposed method
By analogy with the fetal allograft we propose the following new approach to organ transplantation with special reference to kidney transplantation, which is the most commonly practised form of transplant. The approach is subdivided into tissue matching and immunosuppressive treatment.
TWO-WAY MIXED LYMPHOCYTE REACTION
Using the analogy of the fetal graft, and contrary to what is usually accepted, the two-way MLR is apparently a better indicator of tissue compatibility than the one-way MLR, and this is borne out by the available data on kidney transplantation. The one-way MLR does not correlate with graft survival as measured in a retrospective survey." Nevertheless, evidence from two groups of workers, again using retrospective evidence, suggests that the two-way MLR does correlate with graft survival.'2 131 If the MLR stimulation ratio was less than 8-0 the retrospective graft survival was about 800%, whereas with stimulation ratios greater than 8 0 the success rate fell to 20 %. These results were independent of HLA matching.
This work was not pursued, presumably because the technology available then was such that four days were needed to carry out an MLR, and cadaver kidneys could not be preserved that long. Recent work,14 however, has suggested that one of the reacting cells in an MLR can be primed by prestimulation with phytohaemagglutinin (PHA), and then stored in liquid nitrogen. These primed cells will react almost immediately with another cell populaaion, so that a result may be available within 36 to 48 hours. This is well within the period for which a cadaver kidney can be stored and still function normally. A retrospective survey would be needed to determine whether the results obtained by this method are comparable with the two-way technique using fresh cells.
In practical terms we would suggest that the local recipient pool of patients awaiting kidney transplants should have samples of their PHA-primed lymphocytes stored in liquid nitrogen. When a donor becomes available the donor lymphocytes could then be tested against the panel of ABO compatible primed recipient lymphocytes and the results read positively within 36 hours. A range of reactions would be obtained and those with minimal reactivity, and ideally with a stimulation ratio of less than 8-0, would be considered for transplantation. Our data show that about 20 % of two-way MLRs between random controls result in a minimal reaction, and hence a recipient pool of 20 patients should be adequate to provide a good match in most cases. Thus most centres could be independent.
IMMUNOSUPPRESSIVE TREATMENT
Our results show that immunosuppressive treatment can control the weak reaction between well-matched cells, but cannot overcome the much stronger reaction between grossly incompatible cells. 6 Increasing the dose of drugs in poorly matched transplants simply produces increased toxicity without conferring additional protection to the graft. This finding is compatible with the clinical experience of McGeown et al,15 who have pointed out that infection is a major cause of death in patients who receive transplants, and that better results are obtained by using moderate doses of immunosuppressive agents. We agree with this view and with the immnunosuppressive regimen they suggest.
We would suggest, however, that the standard, potentially toxic drug regimen (azathioprine and prednisone) might eventually be replaced by the natural immunosuppressive agents produced in pregnancy, which are both highly effective and non-toxic when the fetal graft is well matched. These agents include x-fetoprotein and chorionic gonadotrophin. We suggest, however, that in the interim transplant surgeons could supplement and partially replace the current, potentially toxic regimen by regular infusions offairly large volumes ofplasma taken from pregnant women, since this should contain the naturally occurring immunosuppressive agents. These infusions might be needed only for the first month, after which maintenance treatment with small doses of standard drugs would probably be adequate.
Comment
The two-way MLR seems to explain fetal allograft survival, and retrospective surveys suggest that this test could be used to select compatible donor-recipient transplant pairs. Additional evidence shows that the relatively weak reaction between compatible cells can-be eliminated by moderate doses of immunosuppressive treatment, possibly using naturally occurring immunosuppressive agents produced in pregnancy. As an interim measure plasma from pregnant women could either supplement or partially replace stalndard immunosuppressive treatment.
Will this approach work? Retrospective surveys show that an 800%', success rate may be expected, provided that the two-way MLRs using PHA-primed cells can be shown to give the same results as the ordinary two-way MLR. Even if this does not tuirn out to be the case other methods of speeding up the MLR can probably be developed.
